Abstract
Cisplatin or cis-diamminedichloroplatinum (CDDP) is the first member of a class of
platinum-containing anti-cancer drugs that act by binding to and causing cross-linking
of deoxyribonucleic acid, which ultimately triggers apoptosis. Cisplatin has a broad-spectrum
antineoplastic activity against various types of human tumors. Unfortunately, the
optimal usefulness of Cisplatin is limited secondary to its dose related toxicity
especially nephrotoxicity. Cisplatin chemotherapy is also associated with cardiotoxic
effects that may range from silent arrhythmias to heart failure and even sudden cardiac
death. These effects are more pronounced when cisplatin is combined with other cardiotoxic
drugs. Here, we report a case of patient of cancer lung who developed paroxysmal supraventricular
tachycardia following administration of Cisplatin. A brief review of the literature
follows.
Keywords
Cisplatin - lung cancer - paroxysmal supraventricular tachycardia
